Lab Med Online.  2016 Jul;6(3):152-158. 10.3343/lmo.2016.6.3.152.

Comparing the Efficacy of Samsung LABGEO PT10 and Bio-Rad Variant II Turbo for HbA1c Measurement in Three Types of Blood Samples

• Park JE
• Park HD

• KMID: 2308730
• DOI: http://doi.org/10.3343/lmo.2016.6.3.152

Abstract

BACKGROUND
Hemoglobin A1c (HbA1c) is a good marker for monitoring glycemic control. The Samsung LABGEO PT10 HbA1c test (Samsung Electronics, Korea) was developed as a point-of-care testing approach. This study evaluated the levels of HbA1c in three different types of blood specimens using two different methods.
METHODS
We used correlation analyses to compare the results obtained using Samsung LABGEO PT10 and Bio-Rad Variant II Turbo (Bio-Rad Laboratories, USA) to determine the levels of HbA1c in three different types of blood samples: capillary blood, EDTA whole blood, and lithium (Li)-heparin whole blood.
RESULTS
The correlation coefficient for the level of HbA1c in capillary blood based on LABGEO PT10 vs. that in EDTA whole blood based on the Variant II Turbo was r=0.9619; that in capillary blood based on LABGEO PT10 vs. that in Li-heparin whole blood based on the Variant II Turbo was r=0.9619; that in capillary blood vs. that in EDTA whole blood based on the LABGEO PT10 was r=0.9697; that in capillary blood vs. that in Li-heparin whole blood based on the LABGEO PT10 was r=0.9724; and that in EDTA whole blood vs. that in Li-heparin whole blood based on the LABGEO PT10 was r=0.9730.
CONCLUSIONS
The LABGEO PT10 was suitable for analyzing HbA1c. The results for the measurement of HbA1c levels in capillary blood were comparable to that in the whole blood samples. Additionally, LABGEO PT10 can be used for patients who are unable to take venipuncture.

Keyword

Comparison; Diabetes; Hemoglobin A1c; Point-of-care; Sample type

MeSH Terms

Capillaries
Edetic Acid
Humans
Lithium
Phlebotomy
Point-of-Care Systems
Point-of-Care Testing
Edetic Acid
Lithium

Figure

• 

  Fig. 1 Comparison of HbA1c levels for capillary blood by LABGEO PT10 vs. EDTA whole blood and Li-heparin whole blood by Variant II Turbo. Comparisons were made using Passing-Bablok regression plots and Bland-Altman plots. (A) Capillary blood by LABGEO PT10 vs. EDTA whole blood by Variant II Turbo, (B) Capillary blood by LABGEO PT10 vs. Li-heparin whole blood by Variant II Turbo. In the Passing-Bablok regression plots: thick solid line, linear regression; dashed lines, 95% confidence interval for the regression line; thin dotted line, theoretical line with a slope of 1.0 and a Y intercept of 0. In the Bland-Altman plots: solid line, mean of concentration differences; dashed lines, limits of agreement (means of concentration differences between two assays±1.96 SD). Abbreviations: PT10, Samsung LABGEO PT10; Variant II, Bio-Rad Variant II Turbo; WB, whole blood; LH, Li-heparin.

• 

  Fig. 2 Sample-type comparison of HbA1c levels by LABGEO PT10. Comparisons using Passing-Bablok regression plots and Bland-Altman plots (A) Capillary blood vs. EDTA whole blood, (B) Capillary blood vs. Li-heparin whole blood, and (C) EDTA whole blood vs. Li-heparin whole blood. In Passing-Bablok regression plots: thick solid line, linear regression; dashed lines, 95% confidence interval for the regression line; thin dotted line, theoretical line with a slope of 1.0 and a Y intercept of 0. In Bland-Altman plots: solid line, mean of concentration differences; dashed lines, limits of agreement (means of concentration differences between two assays±1.96 SD). Abbreviations: PT10, Samsung LABGEO PT10; Variant II, Bio-Rad Variant II Turbo; WB, whole blood; LH, Li-heparin.

Reference

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329:977–986.

2. World Health Organization. WHO diabetes media centre. Updated on Jan 2015. http://www.who.int/mediacentre/factsheets/fs312/en/index.html.

3. Steffes M, Cleary P, Goldstein D, Little R, Wiedmeyer HM, Rohlfing C, et al. Hemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study. Clin Chem. 2005; 51:753–758.

4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37:Suppl 1. S81–S90.

5. St John A, Davis TM, Goodall I, Townsend MA, Price CP. Nurse-based evaluation of point-of-care assays for glycated haemoglobin. Clin Chim Acta. 2006; 365:257–263.

6. Miller CD, Barnes CS, Phillips LS, Ziemer DC, Gallina DL, Cook CB, et al. Rapid A1c availability improves clinical decision-making in an urban primary care clinic. Diabetes Care. 2003; 26:1158–1163.

7. Jeong TD, Lee W, Chun S, Min WK. Performance evaluation of the LABGEO PT10 point-of-care chemistry analyzer. J Lab Med Qual Assur. 2013; 35:70–80.

8. Clinical and Laboratory Standards Institute. Measurement procedure comparison and bias estimation using patient samples: approved guideline. Wayne, PA: CLSI;2013.

9. Clinical and Laboratory Standards Institute. Evaluation of matrix effects: approved guideline. Wayne, PA: Clinical and Laboratory Standards Institute;2005.

10. Altman DG, editor. Practical statistics for medical research. London: New York: Chapman and Hall;1991.

11. Solvik UO, Roraas T, Christensen NG, Sandberg S. Diagnosing diabetes mellitus: performance of hemoglobin A1c point-of-care instruments in general practice offices. Clin Chem. 2013; 59:1790–1801.

12. Weykamp C, John WG, Mosca A, Hoshino T, Little R, Jeppsson JO, et al. The IFCC Reference Measurement System for HbA1c: a 6-year progress report. Clin Chem. 2008; 54:240–248.

13. Little RR, Roberts WL. A review of variant hemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol. 2009; 3:446–451.

14. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 2001; 47:153–163.

15. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011; 57:e1–e47.

16. Lenters-Westra E, Slingerland RJ. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem. 2010; 56:44–52.